Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial

NCT07226622 · View on ClinicalTrials.gov ↗

Study Summary

The aim of this study is to inform and improve future clinical trials in Wilson Disease (WD) by better understanding how patients with WD are living with and managing the disease, and by identifying key factors that shape their decisions to participate in clinical research.

Conditions Studied

Study Locations (7)

California

  • University of California Los Angeles Medical Center — Los Angeles
  • University of California Davis Health — Sacramento

Connecticut

  • Yale New Haven Hospital — New Haven

Illinois

  • Northwestern University — Chicago

Massachusetts

  • Massachusetts General Hospital — Boston

Michigan

  • University of Michigan Medicine — Ann Arbor

Texas

  • American Research Corporation — San Antonio

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-12-29
Est. Completion 2027-12

Sponsor

Prime Medicine

29 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07226622

The ClinicalTrials.gov registry entry for NCT07226622 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prime Medicine, which has 29 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Wilson Disease appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07226622 reports 7 study locations spanning 6 distinct geographic areas — top geographies include California, Connecticut, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07226622 about?

NCT07226622 is a clinical study titled "Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial". The aim of this study is to inform and improve future clinical trials in Wilson Disease (WD) by better understanding how patients with WD are living with and managing the disease, and by identifying key factors that shape their decisions to participate in clinical research.

What is the current status of trial NCT07226622?

This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2025-12-29. Estimated completion is 2027-12.

What conditions does trial NCT07226622 study?

This clinical trial studies the following conditions: Wilson Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT07226622?

This trial is sponsored by Prime Medicine, which has 29 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07226622 being conducted?

This trial has 7 study locations across California, Connecticut, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial